Endpoints News

Eli Lilly's Omvoh approved for Crohn's disease		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T W Thu F

16 January, 2025

Corval is a cutting-edge technology solution that enables teams to quickly create a multi-year roadmap with a companion budget and resource plan through launch.

sponsored by Corval

news

Bioregnum

A mixed year for deals and dollars left biotech execs hungry for a better 2025

Eli Lilly's Omvoh earns FDA approval for Crohn's disease

FDA explains why it rejected Vanda's stomach drug in late 2024

Jan 29

12:00pm ET

What’s on the horizon? The next era of alzheimer's treatments and diagnostics

sponsored by Alzheimer's Drug Discovery Foundation

Feb 04

12:00pm ET

New data: Optimizing breast cancer care and drug development with molecular residual disease testing

in case you missed it

Oncology biotech plots expedited approval for bone cancer drug after Phase 2 win

Samsung Bio eyes construction of sixth manufacturing plant to kickstart 2025

News Briefing

Hinge Bio's $30M raise; Keros reports additional issues in Phase 2 PAH trial

WuXi Companies See Growth After ‘Very Limited’ Biosecure Impact

How a Company Makes Millions Off a Hospital Program Meant to Help the Poor

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Preclinical R&D Strategy Expert, Therapeutic Antibody

Creative Biolabs

Shirley, NY

Senior Manager - Regulatory Affairs

Bioplus Life Sciences

Bangalore, Karnataka, India

Recruit talent with Endpoints Careers

Contact Meg Estacio: mestacio@endpointsnews.com

As the JP Morgan conference winds down, thoughts turn to what 2025 might bring. Founding editor John Carroll has taken one last look at the numbers for 2024 and mulls some possibilities for the coming year.